PDF下载 ( 1544 KB)
Research advances in immunotherapy for chronic hepatitis B
-
摘要:
目前核苷和核苷酸类药物及IFNα对慢性乙型肝炎(CHB)患者的治疗效果仍有限,因此,开发更有效的治疗策略来提高CHB的疗效至关重要。介绍了CHB的免疫治疗,包括治疗性疫苗(蛋白类疫苗、DNA疫苗、树突状细胞疫苗)和细胞调节治疗。认为免疫治疗是治疗HBV感染的一个很有前景的治疗方案。随着对HBV感染后临床转归机制的进一步深入研究,CHB的免疫治疗研究也取得了显著进展。
Abstract:At present,nucleos( t) ide analogues and interferon-α still have limited effects in patients with chronic hepatitis B( CHB),and therefore,it is of vital importance to develop more effective therapeutic strategies to improve the treatment outcome of CHB patients. This article introduces the immunotherapy for CHB,including therapeutic vaccines( protein vaccines,DNA vaccines,and dendritic cell vaccines)and cell regulation therapy,and points out that immunotherapy is considered a promising treatment regimen for HBV infection. With further studies on the clinical outcome after HBV infection,significant advances have been achieved in immunotherapy for CHB.
-
Key words:
- hepatitis B /
- chronic /
- immunotherapy
-
[1]ZOULIM F,DURANTEL D.Antiviral therapies and prospects for a cure of chronic hepatitis B[J].Cold Spring Harb Perspect Med,2015,5(4):a021501. [2]BERTOLETTI A,FERRARI C.Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut,2012,61(12):1754-1764. [3]BACKES S,JGER C,DEMBEK CJ,et al.Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice[J].Vaccine,2016,34(7):923-932. [4]KOSINSKA AD,JOHRDEN L,ZHANG E,et al.DNA primeadenovirus boost immunization inducesa vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model[J].J Virol,2012,86(17):9297-9310. [5]MARTIN P,DUBOIS C,JACQUIER E,et al.TG1050,an immunotherapeutic to treat chronic hepatitis B,induces robust T cells and exerts an antiviral effect in HBV-persistent mice[J].Gut,2015,64(12):1961-1971. [6]YANG HC,KAO JH.HBV cure-can we pin our hopes on immunotherapy?[J].Nat Rev Gastroenterol Hepatol,2015,12(3):129-131. [7]LI J,GE J,REN S,et al.Hepatitis B surface antigen(HBs Ag)and core antigen(HBc Ag)combine Cp G oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection[J].Vaccine,2015,33(35):4247-4254. [8]DAI S,ZHUO M,SONG L,et al.Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice[J].Immunobiology,2016,221(7):813-821. [9]BONI C,FISICARO P,VALDATTA C,et al.Characterization of hepatitis B virus(HBV)-specific T-cell dysfunction in chronic HBV infection[J].J Virol,2007,81(8):4215-4225. [10]LU M,YAO X,XU Y,et al.Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model[J].J Virol,2008,82(5):2598-2603. [11]SPELLMAN M,MARTIN JT.Treatment of chronic hepatitis B infection with DV-601,a therapeutic vaccine(abstract)[J].J Hepatol,2011,54:s302. [12]SCHIOTT A,LARSSON K,MANNICHE S,et al.Posintro TMHBs Ag,a modified ISCOM including HBs Ag,induces strong cellular and humoral responses[J].Int J Pharm,2011,414(1-2):312-320. [13]BUCHMANN P,DEMBEK C,KUKLICK L,et al.A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance inhepatitis Bvirus(HBV)transgenic mice[J].Vaccine,2013,31(8):1197-1203. [14]KING TH,KEMMLER CB,GUO Z,et al.A whole recombinant yeast-based therapeutic vaccine elicits HBV X,S and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance[J].PLo S One,2014,9(7):e101904. [15]MANCINI-BOURGINE M,FONTAINE H,BRECHOT C,et al.Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers[J].Vaccine,2006,24(21):4482-4489. [16]MANCINI-BOURGINE M,FONTAINE H,SCOTT-ALGARA D,et al.Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers[J].Hepatology,2004,40(4):874-882. [17]LAYEK B,LIPP L,SINGH J.APC targeted micelle for enhanced intradermal delivery of hepatitis B DNA vaccine[J].J Control Release,2015,207:143-153. [18]LIU KH,ASCENZI MA,BELLEZZA CA,et al.Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks[J].J Virol,2011,85(10):4853-4862. [19]WANG YZ,WANG SF,ZHANG XJ,et al.Cellular and humoral immune responses to heat shock protein HSP70 and gp96 enhanced DNA vaccine[J].Chin J Biotech,2011,27(5):790-798.(in Chinese)王彦中,王赛峰,张小俊,等.热休克蛋白HSP70和gp96增强乙型肝炎DNA疫苗的细胞和体液免疫应答[J].生物工程学报,2011,27(5):790-798. [20]QING Y,CHEN M,ZHAO J,et al.Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV transgenic mice[J].Vaccine,2010,28(26):4301. [21]WANG X,DONG A,XIAO J,et al.Overcoming HBV immune tolerance to eliminate HBs Ag-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice[J].Cell Mol Immunol,2015.[Epub ahead of print] [22]LIN C,ZHU J,ZHENG Y,et al.Effect of GM-CSF in combination with hepatitis B vaccine on revaccination of healthy adult nonresponders[J].J Infect,2010,60(4):264-270. [23]OVERTON ET,SUNGKANUPARPH S,KLEBERT,et al.GMCSF fails to improve immune responses to booster hepatitis B vaccination in HIV-infected individuals[J].Open Virol J,2011,5:109-113. [24] CHEN S,LAN YH,LI YG.The role of dendritic cells in the pathogenesis of chronic hepatitis B and the research of vaccine dendritic cell[J].Int J Immunol,2009,32(6):446-449.(in Chinese)陈姝,兰英华,李用国.树突状细胞与乙型肝炎慢性化的关系及树突状细胞疫苗相关研究进展[J].国际免疫学杂志,2009,32(6):446-449. [25]AKBAR SM,CHEN S,Al-MAHTAB M,et al.Strong and multi-antigen specific immunity by hepatitis B core antigen(HBc Ag)-based vaccines in a murine model of chronic hepatitis B:HBc Ag is a candidate for a therapeutic vaccine against hepatitis B virus[J].Antiviral Res,2012,96(1):59-64. [26]FARAG MM,TEDJOKUSUMO R,FLECHTENMACHER C,et al.Immune tolerance against HBVcan be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp[J].Vaccine,2012,30(42):6034-6039. [27]AKBAR SM,FURUKAWA S,HORIIKE N,et al.Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B[J].J Viral Hepat,2011,18(6):408-414. [28]LI F,WEI H,WEI H,et al.Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice[J].Gastroenterology,2013,144(2):392-401. [29]YANG X,WANG XX,QIU MT,et al.Lack of association of three common polymorphisms in toll-like receptors(TLRs),TLR2+597T>C,+1350C>T and Arg753Gln with cancer risk:a metaanalysis[J].Asian Pac J Cancer Prev,2013,14(10):5871-5876. [30]SILLAT T,BARRETO G,CLARIJS P,et al.Toll-like receptors in human chondrocytes and osteoarthritic cartilage[J].Acta Orthop,2013,84(6):585-592. [31]LANFORD RE,GUERRA B,CHAVEZ D,et al.Tumas DB GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517.e10. [32]MENNE S,TUMAS DB,LIU KH,et al.Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B[J].J Hepatol,2015,62(6):1237-1245. [33]GANE EJ,LIM YS,GORDON SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].J Hepatol,2015,63(2):320-328. [34] WANG JZ,YANG DL.Research progress of immune regulation in the treatment of chronic viral infection[J].Chin J Hepatol,2015,23(3):227-230.(in Chinese)王俊忠,杨东亮.免疫调节治疗慢性毒感染的研究进展[J].中华肝脏病杂志,2015,23(3):227-230. [35]SUNG JJ,LI K,YUEN H.HBV-ISS(Dynavax)[J].Curr Opin Mol Ther,2006,8(2):150-155. [36]COOPER C,MACKIE D.Hepatitis B surface antigen-1018 ISS adjuvant.containing vaccine:a review of HEPLISAV safety and efficacy[J].Expert Rev Vaccines,2011,10(4):417-427. [37]MAINI MK,SCHURICH A.The molecular basis of the failed immune response in chronic HBV:therapeutic implications[J].J Hepatol,2010,52(4):616-619. [38]FISICARO P,VALDATTA C,MASSARI M,et al.Combined blockade of programmed death-1 and activation of CD137,increase responses of human liver T cells against HBV,but not HCV[J].Gastroenterology,2012,143(6):1576-1585.e4 [39]LIU J,KOSINSKA A,LU M,et al.New therapeutic vaccination strategies for the treatment of chronic hepatitis B[J].Virological Sinica,2014,29(1):10-16. [40]SCHURICH A,KHANNA P,LOPES AR,et al.Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosisProne CD8 T cells in persistent hepatitis B virus infection[J].Hepatology,2011,53(5):1494-1503. [41]WEBER J.Review:anti-CTLA-4 antibody ipilimumab:case studies of clinical response and immune-related adverse events[J].Oncologist,2007,12(7):864-872. [42]JU Y,HOU N,MENG J,et al.T cell immunoglobulin-and mucin-domain-containing molecule-3(Tim-3)mediates natural killer cell suppression in chronic hepatitis B[J].J Hepatol,2010,52(3):322-329. [43]RAZIORROUH B,SCHRAUTW,GERLACH T,et al.The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD81 T-cell function[J].Hepatology,2010,52(6):1934-1947. -
本文二维码
计量
- 文章访问数: 2053
- HTML全文浏览量: 17
- PDF下载量: 448
- 被引次数: 0
下载:
